Valuation: Theravance Inc

Market Cap 148.1Cr 131.59Cr 122.82Cr 111.94Cr 211.13Cr 14TCr 213.09Cr 1.49TCr 575.94Cr 7.28TCr 556.05Cr 543.98Cr 23TCr P/E 2026 *
9.18x
P/E 2027 * 9.06x
Enterprise Value 96Cr 85Cr 79Cr 72Cr 136.15Cr 9.18TCr 137.42Cr 958.49Cr 371.42Cr 4.69TCr 358.59Cr 350.81Cr 15TCr EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.57x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 42 20/05/2020
Director of Finance/CFO 60 21/08/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 75 12/02/2018
Director/Board Member 66 12/02/2018
Director/Board Member 42 19/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%-3.43%+39.40%+112.31% 1,01900Cr
-1.02%-5.60%+37.67%+65.02% 62TCr
+1.11%-0.58%+11.10%+77.28% 46TCr
+0.34%-3.01%+61.21%+40.71% 36TCr
-0.95%-4.05%+21.60%+39.37% 33TCr
-1.46%-2.89%+11.84%+24.60% 27TCr
-1.35%-5.43%-4.69%+8.40% 24TCr
-1.04%-2.79%+35.52%+51.34% 22TCr
-1.87%-4.10%+30.92%+95.33% 18TCr
Average -0.23%-3.39%+27.17%+57.15% 41.08TCr
Weighted average by Cap. +0.42%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 45Cr 40Cr 37Cr 34Cr 64Cr 4.34TCr 65Cr 452.9Cr 175.5Cr 2.22TCr 169.44Cr 165.76Cr 7.12TCr 49Cr 44Cr 41Cr 37Cr 70Cr 4.71TCr 71Cr 491.76Cr 190.56Cr 2.41TCr 183.97Cr 179.98Cr 7.73TCr
Net income 18Cr 16Cr 15Cr 14Cr 26Cr 1.72TCr 26Cr 179.83Cr 70Cr 880.62Cr 67Cr 66Cr 2.83TCr 17Cr 16Cr 14Cr 13Cr 25Cr 1.68TCr 25Cr 175.14Cr 68Cr 857.67Cr 66Cr 64Cr 2.75TCr
Net Debt -53Cr -47Cr -44Cr -40Cr -75Cr -5.06TCr -76Cr -527.81Cr -204.53Cr -2.58TCr -197.46Cr -193.18Cr -8.3TCr -71Cr -63Cr -59Cr -54Cr -101.49Cr -6.84TCr -102.44Cr -714.5Cr -276.87Cr -3.5TCr -267.31Cr -261.5Cr -11TCr
Logo Theravance Inc
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-